Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celltech Group, Lonza Group deal

Lonza division Lonza Biotec (Visp, Switzerland) will manufacture for CCH PEGylated antibody fragment-based compounds. CCH's

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE